Acrivon reports $159.5M cash as of March 31, 2023; runway into Q4 2024

Acrivon Therapeutics, Inc.

Cash and marketable securities totaled $159.5M as of March 31, 2023 (preliminary, unaudited).
Company confirms cash runway extends into at least the fourth quarter of 2024.
Preliminary estimate subject to change; actual results may differ materially.
Update provided in connection with virtual investor event on May 1, 2023.

item 2.02

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Acrivon Therapeutics, Inc. reported preliminary financial results for the three months ended March 31, 2023.

Period: the three months ended March 31, 2023
Result: preliminary results

Exact text from the filing

Acrivon Therapeutics, Inc. (the “Company”) will be updating its corporate presentation to include disclosure that the Company had $159.5 million of cash and marketable securities as of March 31, 2023 and to confirm its cash runway into at least the fourth quarter of 2024. Because the Company’s financial results for the three months ended March 31, 2023 have not been finalized or audited, the preliminary statement of the Company’s cash and marketable securities as of March 31, 2023 in this Item 2.02 is subject to change

View on SEC.gov

Browse all earnings releases →

Acrivon Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-128896

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.